Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Status: Completed

Protocol number: BA16286

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of dose conversion factors for maintenance subcutaneous Mircera in dialysis patients with chronic renal anemia

Brief summary: This study will determine the appropriate dose and frequency of administration of sc Mircera maintenance therapy in dialysis patients with chronic renal anemia who were previously receiving sc epoetin alfa or beta. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals. Target sample size is 135.

Study phase: II

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Anemia

Intervention type: Drug

Intervention name: methoxy polyethylene glycol-epoetin beta [Mircera]

Primary outcome: 1. Change in hemoglobin from baseline over time under constant dosing regimen Time frame: Throughout study

Key secondary outcomes: 1. Change in hematocrit from baseline over time under constant dosing regimen. Vital signs, adverse events, laboratory values Time frame: Throughout study

Inclusion criteria:

  • adult patients >=18 years of age;
  • chronic renal anemia;
  • on dialysis (hemodialysis or peritoneal dialysis) therapy for at least 3 months;
  • receiving sc epoetin alfa or beta for at least 3 months prior to the run-in period.

Exclusion criteria:

  • women who are pregnant, breastfeeding or using unreliable birth control methods;
  • use of any investigational drug within 30 days preceding the run-in phase, or during the run-in or study treatment period.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Trial registration date: 05/23/2005

Date last updated: 8/29/2008


Link to trial result

This trial was conducted at the following locations:

Germany

  • Berlin
  • Mannheim
  • Villingen-Schwenningen
  • Wiesloch

Italy

  • Bari
  • Bergamo
  • Lecco
  • Lodi
  • Milano
  • Modena
  • Pavia
  • Vicenza

Spain

  • Barcelona
  • Madrid
  • Malaga
  • Santander

United States

  • Los Angeles, CA
  • San Jose, CA
  • Boston, MA
  • Cleveland, OH
  • Houston, TX
  • Morgantown, WV

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply